To investigate whether GTN improved the anti-tumor efficacy of doxorubicin via activation of the immune system, and more particularly CD8 TILs, we tested the impact of an anti-CD8 antibody (ab) on the anti-tumor activity of the treatment combination. This evidence concerns the gene CD8A and neoplasm.